
|Articles|March 29, 2023
Discussing the Growing Role of CDMOs with Anil Kane (DCAT 2023)
Author(s)Grant Playter
Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry
Advertisement
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. In in our discussion, Anil discussed various topics within the outsourcing market, including:
- The increased interest in technologies like cell and gene therapies and oral biologics
- The continued rise of the "end-to-end" CDMO model and why biopharma partners are seeking it out
- Recent investments made in new spaces by Thermo Fisher Scientific
For more of our coverage on DCAT in 2023, viewers can visit
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Peptide Compounding Vote Raises New Questions for Drug Developers
2
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
3
PharmTech Weekly Roundup—July 24, 2026
4
Midyear 2026 Check In: Campbell Bunce of Abzena Talks Antibody-Oligonucleotide Conjugates and Development Timelines
5




